Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper

J Cardiovasc Med (Hagerstown). 2021 Mar 1;22(3):162-171. doi: 10.2459/JCM.0000000000001108.

Abstract

The central role of high low-density lipoprotein cholesterol levels in atherosclerotic cardiovascular disease has led to research focused on lipid-lowering agents for cardiovascular risk reduction. Bempedoic acid is an emerging treatment for hypercholesterolemia that has recently been approved for marketing in the United States and Europe. This review focuses on its mechanism of action and summarizes the main preclinical study findings. Furthermore, we report the clinical evidence supporting and guiding its use in hypercholesterolemia management.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Cholesterol / blood
  • Dicarboxylic Acids / therapeutic use*
  • Fatty Acids / therapeutic use*
  • Humans
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Hypolipidemic Agents / therapeutic use

Substances

  • Biomarkers
  • Dicarboxylic Acids
  • Fatty Acids
  • Hypolipidemic Agents
  • 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
  • Cholesterol